Orkambi and Depression aggravated - a phase IV clinical study of FDA data

Summary:

Depression aggravated is reported as a side effect among people who take Orkambi (ivacaftor; lumacaftor), especially for people who are female, 10-19 old, have been taking the drug for 1 - 2 years also take Pulmozyme, and have Cystic fibrosis.

The phase IV clinical study analyzes which people have Depression aggravated when taking Orkambi. It is created by eHealthMe based on reports of 9,494 people who have side effects when taking Orkambi from the FDA, and is updated regularly.

What is Orkambi?

Orkambi has active ingredients of ivacaftor; lumacaftor. eHealthMe is studying from 9,496 Orkambi users. Check the latest studies of Orkambi.

What is Depression aggravated?

Depression aggravated is found to be associated with 2,419 drugs and 750 conditions by eHealthMe. Check the latest studies of Depression aggravated.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

9,494 people reported to have side effects when taking Orkambi.
Among them, 107 people (1.13%) have Depression aggravated.

Could Orkambi cause Depression aggravated?

Among these 107 people:

How long have people been on Orkambi when they have Depression aggravated? *

Click here to view more results

What is the gender of people who have Depression aggravated when taking Orkambi? *

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Orkambi and have Depression aggravated?

- Check whether Depression aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Orkambi:

Orkambi (9,496 reports)

Depression aggravated treatments and more:

Depression aggravated (2,253 reports)

How severe was Depression aggravated and when was it recovered:

Depression aggravated in Orkambi

Expand to all the drugs that have ingredients of ivacaftor; lumacaftor:

Depression aggravated and drugs with ingredients of ivacaftor; lumacaftor

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Orkambi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Depression aggravated:

Depression aggravated (2,419 drugs)

Browse all the conditions that are associated with Depression aggravated:

Depression aggravated (750 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ivacaftor; lumacaftor (the active ingredients of Orkambi) and Orkambi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.